Invizyne Revenue and Competitors
Estimated Revenue & Valuation
- Invizyne's estimated annual revenue is currently $5M per year.
- Invizyne's estimated revenue per employee is $155,000
Employee Data
- Invizyne has 32 Employees.
- Invizyne grew their employee count by 39% last year.
Invizyne's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder and Director Research Development | Reveal Email/Phone |
2 | Director Research & Development | Reveal Email/Phone |
3 | Research Associate | Reveal Email/Phone |
4 | President & Chairman the Board | Reveal Email/Phone |
Invizyne Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Invizyne?
Nature provides us with countless chemicals that can improve our lives. Trees and plants often supply them, but in such small amounts that they’re hard to extract, leading to waste and environmental degradation. To harness natural chemicals more effectively, synthetic biology first attempted to rewire living cells to make them easier to extract. But cells are complicated and not easily rewired. Invizyne’s new approach, SimplePath streamlines synthetic biology by removing cells altogether, along with their complexities. Using our proprietary, sustainable enzyme systems we can build simple, efficient reactors for chemical production.
keywords:N/AN/A
Total Funding
32
Number of Employees
$5M
Revenue (est)
39%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.5M | 33 | 10% | N/A |
#2 | $9.6M | 34 | -3% | N/A |
#3 | $6.6M | 34 | -15% | N/A |
#4 | $2.9M | 36 | 0% | N/A |
#5 | $8.6M | 37 | 9% | N/A |